Articles tagged with "Epidiolex"
11 total articles - Page 1 of 2
DEA loosens rules on prescription CBD drug Epidiolex
David Downs - Published on April 6, 2020Read morePrescription CBD tincture Epidiolex is coming to more patients. Cost: $32,500 per year.
FAQ: What to Know About the DEA’s CBD Rescheduling Order
Ben Adlin - Published on September 28, 2018Read moreFor one, it doesn’t actually reschedule CBD.
What’s Next for Epidiolex Maker GW Pharmaceuticals
Ben Adlin - Published on June 28, 2018Read moreLeafly spoke with VP Stephen Schultz about the significance of FDA approval, when Epidiolex might become available to patients, and what’s coming next from the drugmaker.
Why June 2018 Will Go Down as the Month Prohibition Crumbled
Bruce Barcott - Published on June 27, 2018Read moreCanada, Oklahoma, and the FDA: Here’s how each delivered a mortal blow to cannabis prohibition this month.
Is CBD Oil Legal Now? With Epidiolex Approved, It’s Still Not Clear
Ben Adlin - Published on June 25, 2018Read moreThe FDA just approved the CBD drug Epidiolex. Here’s what that means for the legal status of CBD oil nationwide.
FDA Approves Epidiolex, a Marijuana-Based CBD Drug for Seizures
The Associated Press - Published on June 25, 2018Read moreThe Food and Drug Administration approved Epidiolex to treat two rare forms of epilepsy that begin in childhood. But it’s not quite medical marijuana.
Is FDA-Approved Cannabidiol a Blessing or Curse?
The Associated Press - Published on June 19, 2018Read moreAs the marijuana molecule cannabidiol nears FDA-approval, parents who for years have used cannabis to treat severe forms of epilepsy in their children are feeling more cautious than celebratory.
Study Finds CBD Drug Epidiolex Reduces Seizures by 42%
Ryan Basen - Published on May 16, 2018Read moreHigh daily doses of CBD significantly reduced seizures in patients with Lennox-Gastaut syndrome.
GW Pharma Responds: ‘Not Creating a Monopoly’
Bruce Barcott - Published on February 22, 2017Read moreThe pharmaceutical developer says it’s pioneering markets, not elbowing out competitors.
Leafly Exclusive: GW Pharma Is Moving CBD Bills on the Down Low
Bruce Barcott - Published on February 17, 2017Read moreThe proposed state measures would give the British pharma company’s new drug–but not other CBD products–legal status.